Coya Therapeutics (COYA) Net Margin (2023 - 2026)
Coya Therapeutics (COYA) posted Net Margin of 2869.63% for Q1 2026, down 1226.31% sequentially from 216.36% in Q4 2025, and down 3628.0% YoY from 81.34% in Q1 2025.
Coya Therapeutics (COYA) Net Margin (2023 - 2026) Analysis & Trends
Coya Therapeutics has reported Net Margin for 4 years, with the latest figure at 2869.63% in Q1 2026.
- Quarterly Net Margin fell 3628.0% year-over-year to 2869.63% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 336.71% (up 49833.0% YoY) and the FY2025 annual result came in at 268.11%, up 15113.0% from the prior year.
- Net Margin fell to 2869.63% in Q1 2026 per COYA's latest filing, from 216.36% in the prior quarter.
- Over five years, Net Margin peaked at 63.48% in Q4 2023 and troughed at 625479.97% in Q4 2024.
- A 4-year average of 71043.53% and a median of 2833.35% in 2025 frame the typical range for Net Margin.
- The sharpest annual moves came in 2024 and 2025: Net Margin plunged 62541649 bps in 2024, then jumped 62526361 bps in 2025.
- Over 4 years, Net Margin stood at 63.48% in 2023, then plunged by 985280 bps to 625479.97% in 2024, then jumped by 100 bps to 216.36% in 2025, then tumbled by 1226 bps to 2869.63% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 2869.63%, 216.36%, and 136.4% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 12.74% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -3.12% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -16.51% |
| 10 | Coya Therapeutics | 113.30 Mn | 70.10 Mn | - | -2,723.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2,723.44% |
| Mar 31, 2026 | -2,869.63% |
| Dec 31, 2025 | -216.36% |
| Sep 30, 2025 | -136.40% |
| Jun 30, 2025 | -3,725.17% |
| Mar 31, 2025 | -2,833.35% |
| Dec 31, 2024 | -625,479.97% |
| Jun 30, 2024 | -84.42% |
| Mar 31, 2024 | -3,982.96% |
| Dec 31, 2023 | -63.48% |